Clinical trials: Refractory Neoplasm
Prostate Cancer
Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Combining calcitriol with dexamethasone may increase the effectiveness of therapy by making cancer cells more sensitive to dexamethasone.
- Trial name
- NCT00010231
- Testing
- calcitriol, dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pittsburgh
Refractory Plasma Cell Myeloma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment.
- Trial name
- NCT01646762
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult subjects with advanced refractory solid tumor malignancies, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose…
- Trial name
- NCT03790488
- Testing
- JTX-4014
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Jounce Therapeutics, Inc.
B-cell Non-Hodgkin Lymphoma
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT04296461
- Testing
- Welgenaleucel
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- UWELL Biopharma
Leukemia
Aminopterin in Treating Patients With Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory…
- Trial name
- NCT00003305
- Testing
- aminopterin, leucovorin calcium
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Myeloproliferative Disorders, Leukemia
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes
- Trial name
- NCT00005622
- Testing
- cyclophosphamide, TBI
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed and/or Refractory Multiple Myeloma
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
- Trial name
- NCT06153251
- Testing
- BMS-986453, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, France and 2 more
- Volunteers
- 187 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Meningioma, Refractory Meningioma
A Study of ONC201 for Refractory Meningioma
The goal of this clinical trial is to learn about treatment for a type of brain tumor called a meningioma. This study will enroll two groups of people.
- Conditions
- Meningioma, Refractory Meningioma, Relapsed Meningioma
- Trial name
- NCT06012929
- Testing
- ONC201
- Sponsor
- University of Nebraska
Leukemia, Myeloid, Acute, Leukemia, Lymphoid
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic
- Trial name
- NCT00569179
- Testing
- CliniMACS CD34 Reagent System
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01676961
- Testing
- romiplostim
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Pediatric Cancer
Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors
Cancer remains the first cause of death due to disease in children and adolescents despite important progress and 70% of the survivors present sequelae.
- Trial name
- PROVIN (NCT02897986)
- Testing
- administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Myeloid Malignancies
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease.
- Trial name
- NCT06930651
- Testing
- Dexamethasone, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Tumors
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there.
- Trial name
- NCT00129337
- Testing
- Bavituximab
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Peregrine Pharmaceuticals
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies.
- Trial name
- NCT04684472
- Testing
- Modified anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liqun Zou
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Fallopian Tube Cancer, Ovarian Cancer
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00019461
- Testing
- carboxyamidotriazole, chemotherapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01096342
- Testing
- dinaciclib, laboratory biomarker analysis
- Where
- 6 sites in United States, Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304005
- Testing
- laromustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vion Pharmaceuticals
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, total-body irradiation, and rituximab before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00387959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.